

## **AMENDMENTS TO THE CLAIMS**

**1 to 10. (Canceled)**

**11. (New)** Method for the production of a stable injectable formulation of poorly soluble antineoplastic agents, wherein a formulation comprising the antineoplastic agent and a solvent and/or a solvent system, which optionally contains a solubilizing agent, is treated with a cation exchanger.

**12. (New)** Method as claimed in claim 11, wherein the antineoplastic agent is paclitaxel, camptothecine or teniposide.

**13. (New)** Method as claimed in claim 12, wherein the antineoplastic agent is paclitaxel.

**14. (New)** Method as claimed in claim 11, wherein the content of the active agent in the solution is 1 - 10 mg/ml.

**15. (New)** Method as claimed in claim 14, wherein the content of the active agent paclitaxel is 4-8 mg/ml.

**16. (New)** Method as claimed in claim 15, wherein the content of the active agent paclitaxel is 6 mg/ml.

**17. (New)** Method as claimed in claim 11, wherein as the solvent or solvent system with solubilizing agent are utilized ethanol, ethanol/polyoxyethylene castor oil, ethanol/polysorbate and ethanol/polyethylene glycol.

**18. (New)** Method as claimed in claim 17, wherein the content of ethanol in the solvent system ethanol/polyoxyethylene castor oil is 10 - 90 parts.

**19. (New)** Method as claimed in claim 17, wherein the content of ethanol in the solvent system ethanol/polysorbate is 40 - 60 parts.

**20. (New)** Method as claimed in claim 11, wherein as the cation exchanger an ion exchanger containing sulfonic acid groups or carboxylate groups is employed.

**21. (New)** Method as claimed in claim 11, wherein the quantity of the cation exchanger is 0.01 - 10% of the total batch.